Media headlines about Biostar Pharmaceuticals (NASDAQ:BSPM) have been trending somewhat negative on Sunday, Accern Sentiment Analysis reports. The research group rates the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Biostar Pharmaceuticals earned a news sentiment score of -0.13 on Accern’s scale. Accern also gave press coverage about the company an impact score of 49.7078671892147 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Separately, ValuEngine cut Biostar Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, June 9th.

Shares of Biostar Pharmaceuticals (NASDAQ BSPM) traded up 1.45% during trading on Friday, reaching $1.39. The company had a trading volume of 26,421 shares. Biostar Pharmaceuticals has a 12 month low of $1.20 and a 12 month high of $7.06. The stock’s market capitalization is $3.70 million. The stock’s 50-day moving average price is $1.41 and its 200-day moving average price is $1.85.

TRADEMARK VIOLATION WARNING: This piece was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at

Biostar Pharmaceuticals Company Profile

Biostar Pharmaceuticals, Inc (Biostar) is a holding company. The Company, through its subsidiary, Shaanxi Biostar Biotech, Ltd. (Shaanxi Biostar), and its variable interest entities (VIEs), Shaanxi Aoxing Pharmaceutical Co, Ltd. (Aoxing Pharmaceutical) and Shaanxi Weinan Huaren Pharmaceuticals Ltd. (Shaanxi Weinan), develops, manufactures and markets pharmaceutical products for various diseases and conditions in the People’s Republic of China (PRC or China).

Insider Buying and Selling by Quarter for Biostar Pharmaceuticals (NASDAQ:BSPM)

Receive News & Ratings for Biostar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostar Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.